Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gynecologic 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 377Carcinoid Tumor 40Gastro-enteropancreatic neuroendocrine tumor 36Pancreatic Neoplasms 27Carcinoma, Neuroendocrine 27Neoplasms 25Adenoma, Islet Cell 23Neoplasm Metastasis 17Pheochromocytoma 16Paraganglioma 16Stomach Neoplasms 15Neuroblastoma 14Gastrointestinal Neoplasms 14Carcinoma, Hepatocellular 12Thyroid Neoplasms 11Prostatic Neoplasms 11Breast Neoplasms 11Sarcoma 10Esophageal Neoplasms 10Colorectal Neoplasms 10Lung Neoplasms 9Rectal Neoplasms 8Gastrointestinal Stromal Tumors 8Cholangiocarcinoma 8Carcinoma 8Brain Neoplasms 8Anus Neoplasms 8Liver Neoplasms 7Colonic Neoplasms 7Carcinoma, Medullary 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Flushing × NET × Clear all
NCT01886287 2015-01-12

P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
2 enrolled 4 charts
EndocrineNET

Diarrhea, Flushing, Neoplasm Metastasis, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡